---
document_datetime: 2026-01-16 16:14:26
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ervebo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ervebo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3326347
conversion_datetime: 2026-01-17 13:05:06.193455
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ervebo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                         |
|---------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000280470 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL | 27/11/2025                          |                                             | SmPC and PL                      | Please refer to Scientific Discussion 'Ervebo-H-C- 004554-II-EMA/VR/0000280470' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted  C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted  A grouped application consisting of: C.I.4: To update sections 4.4, 4.8, 5.1 of the SmPC to include safety and immunogenicity data following the results from study referred to as V920-015 ACHIV, listed as a category 3 study in the RMP; this is a Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to evaluate the safety and immunogenicity of the V920/Ervebo (rVSV Î” G-ZEBOV-GP) Ebola virus vaccine candidate in HIV-Infected adults and adolescents. The RMP version 3.0 has also been submitted. In addition, the Applicant took the opportunity to remove the complete list of local representatives, as suggested by the EMA during the review of   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | specimens for the current ongoing renewal. Instead, the contact details of the MAH are included for ease of contact. C.I.11.b: Submission of an updated RMP version 3.0 in order to summarize the safety and effectiveness of Ervebo administered in the context of Expanded Access Protocol (EAP) 5 compassionate ring vaccination study.   |            |     |      |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-------------|
| PSUR / EMA/PSUR/0000288234            | - -                                                                                                                                                                                                                                                                                                                                          | 27/11/2025 |     |      | Maintenance |
| Variation type IB / EMA/VR/0000305091 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                      | 31/10/2025 |     | SmPC |             |
| Variation type IB / EMA/VR/0000293813 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                            | 23/09/2025 | N/A |      |             |
| Variation type IB / EMA/VR/0000292583 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where                                                                               | 11/09/2025 | N/A |      |             |

<div style=\"page-break-after: always\"></div>

|                                     | no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |            |            |                                  |                                                                                                                                                                                                                                                                      |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000265014 | - Renewal - The renewal is recommended to be granted with unlimited validity.                                                                                                                                                                      | 24/07/2025 | 17/09/2025 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ervebo in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |